Abiopharma

🔍 Golwas Douglas P (Executive)

Company: Medline Inc. (MDLN)

Report Date: 2026-06-15

Detailed Transactions and Holdings:

• Sold 1,889 shares of Class A Common Stock at $36.61 per share (Direct)
  Date: 2026-06-15 | Code: F | equity_swap_involved: false | shares_owned_after: 23,899.00 | transaction_form_type: 4 | Footnotes: F1
• Acquired 100,000 shares of Class A Common Stock (Direct)
  Date: 2026-06-16 | Code: M | equity_swap_involved: false | shares_owned_after: 123,899.00 | transaction_form_type: 4 | Footnotes: F2
• Sold 61,966 shares of Class A Common Stock at $36.6 per share (Direct)
  Date: 2026-06-16 | Code: S | equity_swap_involved: false | shares_owned_after: 61,933.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 38,034 shares of Class A Common Stock at $37.05 per share (Direct)
  Date: 2026-06-16 | Code: S | equity_swap_involved: false | shares_owned_after: 23,899.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Sold 100,000 shares of Class B Common Stock (Direct)
  Date: 2026-06-16 | Code: D | equity_swap_involved: false | shares_owned_after: 365,864.00 | transaction_form_type: 4 | Footnotes: F6, F6
• Sold 100,000 shares of Common Units of Medline Holdings, LP (Derivative)
  Date: 2026-06-16 | Code: M | equity_swap_involved: false | shares_owned_after: 365,864.00 | transaction_form_type: 4 | Footnotes: F2, F2, F2, F2

Footnotes:

• F1: Reflects shares withheld to satisfy the Reporting Person's tax liability in connection with the vesting of restricted stock units.
• F2: Pursuant to the terms of an exchange agreement, dated as of December 16, 2025, holders have the right to exchange their common units of Medline Holdings, LP ("Common Units") for shares of Medline Inc.'s (the "Issuer") Class A common stock ("Class A Common Stock") on a one-for-one basis, subject to customary conversion rate adjustments for stock splits, stock dividends and reclassifications. These exchange rights do not expire. Such Common Units were held indirectly through Medline Management Aggregator LLC.
• F3: Reflects sales effected pursuant to a Rule 10b5-1 trading plan adopted on March 11, 2026.
• F4: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $35.98 to $36.9785 per share, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $36.98 to $37.19 per share, inclusive. The Reporting Persons undertake to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: Shares of the Issuer's Class B common stock ("Class B Common Stock") have no economic value and have one vote per share. One share of Class B Common Stock is issued for each Common Unit held. Upon the exchange of Common Units for shares of Class A Common Stock, an equivalent number of shares of Class B Common Stock were automatically cancelled.